October is Breast Cancer Awareness Month - early detection and the right questions can empower patients to make informed decisions and improve outcomes.

However, it was the late-breaking Phase 1/2 data from the SOHO-01 study of sevabertinib (BAY 2927088) in advanced HER2-mutant non-small cell lung cancer that pharmaphorum spoke about with Dr Nicoletta ...

An MCED blood test increased screenable cancer detection more than 7-fold when added to the US Preventive Services Task Force (USPSTF) A/B recommended screening.

He mentored medical students at UC, held numerous board positions, and remains the top fundraiser for Blood Cancer United's Ohio River Valley Region.He was the face of Peter's Pals at Light the Night.

Hevia and Sousa discuss the landscape of unmet needs in metastatic castration-resistant prostate cancer, what the new data ...

Three years after topping the Medical Technologist Licensure Examination (MTLE) in 2022, the University of Santo Tomas (UST) ...

A blood test that screens for more than 50 cancers is correct in 62% of cases where it thinks people may have the disease, a ...

Atezolizumab improved DFS and OS in ctDNA-positive MIBC patients, with a median DFS of 9.9 months vs 4.8 months for placebo. Serial ctDNA testing may offer a more accurate assessment of MRD and early ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the randomized, double-blind, phase 3 ...

BOWLING GREEN, Ky.- October marks Breast Cancer Awareness Month, and one young survivor is using her voice to raise awareness ...

India’s cancer care sector, valued at Rs 1.25 lakh crore and growing 10–12% annually, is attracting significant private ...

While Natera said it will seek FDA approval for Signatera based on data from IMvigor011, the readout from another ctDNA-guided de-escalation study was more nuanced.